Drug Profile
Monepantel - PharmAust
Alternative Names: PPL-1Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Pitney Pharmaceuticals
- Developer PharmAust
- Class Acetonitriles; Anthelmintics; Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 2 modulators; Cyclin-dependent kinase 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Amyotrophic lateral sclerosis; Motor neuron disease
Most Recent Events
- 13 Feb 2024 Phase-I clinical trials in Motor neuron disease in Australia (PO) (NCT06177431)
- 20 Dec 2023 PharmAust in collaboration with Calvary Health Care and Macquarie University plans a phase I trial in Motor neuron disease in Australia (PO) in January 2024 (NCT06177431)
- 29 Nov 2023 PharmAust completes a phase I trial in Amyotrophic lateral sclerosis in Australia (PO) (NCT04894240)